Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › darunavir

darunavir

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of darunavir

23 trials tracked of darunavir: 11 in phase 3 or 4 and 4 with published results. The most-cited published study has 56 citations.

23Trials tracked
11Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 3 Phase 3 8 Phase 2 5 Phase 1 5 Other / NA 2
  1. Phase 4 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure Completed · 56 cited
  2. Phase 3 Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) Completed · 30 cited
  3. Phase 3 A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women Completed · 28 cited
  4. Phase 3 Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS Completed · 11 cited
  5. Phase 4 Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin Completed
  6. Phase 4 Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment Completed
Show 17 more trials
  1. Phase 3 TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Completed
  2. Phase 3 Optimizing Treatment for Treatment-Experienced, HIV-Infected People Completed
  3. Phase 3 GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men. Completed
  4. Phase 3 A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment Completed
  5. Phase 3 Comparative Study of Three NNRTI-Sparing HAART Regimens Completed
  6. Phase 2 A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children Completed
  7. Phase 2 A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients Completed
  8. Phase 2 Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Completed
  9. Phase 2 A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents Completed
  10. Phase 2 Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen Completed
  11. Phase 1 The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study Completed
  12. Phase 1 Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers Completed
  13. Phase 1 Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz Completed
  14. Phase 1 HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Completed
  15. Phase 1 Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants Completed
  16. N/A Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients. Completed
  17. N/A Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
Infectious Disease RCT
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
May 1, 2026
Integrase inhibitor regimen showed non-inferiority and fewer adverse events versus boosted protease inhibitor in advanced HIV
Infectious Disease RCT
Integrase inhibitor regimen showed non-inferiority and fewer adverse events versus boosted protease inhibitor in advanced HIV Integrase Inhibitors Show Lower Event Rates Than Boosted Protease Inhibitors in Advanced HIV
This trial compared an integrase inhibitor regimen with a boosted protease inhibitor regimen in therapy-naive adults with advanced HIV disea…
A trial of 447 therapy-naive adults with advanced HIV found fewer drug-related side effects with an integrase inhibitor regimen compared to …
May 1, 2026